HER2蛋白活化在HR阳性乳腺癌内分泌耐药中作用的研究进展

激素受体(hormone receptor，HR)阳性乳腺癌约占全部乳腺癌患者的70%，其重要治疗方式为抑制HR通路的内分泌治疗，此型乳腺癌预后虽然相对较好，但仍有30%~40%患者出现内分泌耐药，目前尚未解决。通路间的交联作用在内分泌耐药中发挥重要作用，受体磷酸化是各通路发挥作用的前提，越来越多研究表明人表皮生长因子受体2(human epidermal growth factor receptor 2，HER2)的活化与激素受体阳性乳腺癌内分泌耐药相关，故充分了解HER2蛋白活化与内分泌耐药间的关系，对延缓内分泌耐药具有重要意义。因此本文将顺序阐述HER2蛋白的表达、生物学特性、检测、活化以及HER2蛋白活化在乳腺癌内分泌耐药中的作用，为HR阳性乳腺癌的治疗提供思路。

Advances in the role of HER2 activation in endocrine resistance of HR positive breast cancer

Hormone receptor (HR) positive breast cancer accounts for about 70% of all breast cancer patients，and endocrine therapy aiming to inhibit HR pathway is an effective treatment for it.The prognosis of HR positive breast cancer is better than others，but there are still 30%~40% of patients with endocrine resistance，which has not been resolved.The crosstalk between pathways plays an important role in the endocrine resistance and receptor phosphorylation is the premise of the pathway's activation.Increasing studies have shown that the endocrine resistance is related to the activation of human epidermal growth factor receptor 2 (HER2)，so full understanding of the relationship between HER2 protein activation and endocrine resistance is important to delay the endocrine resistance.Therefore，to provide treatment inspiration for HR positive breast cancer，this paper summarizes in sequence the expression and biological characteristics of HER2 protein，HER2 detection，HER2 activation，and the effect of HER2 protein activation on endocrine efficacy.